Catalent's Stock Plummets After Delayed Earnings and Reduced Guidance Announcement.
Catalent delays its Q3 financial results and investor call due to manufacturing issues at three plants, and expects to cut $400 million in net revenue guidance for the year. BioPharma Solutions is sold for $4.25 billion to Advent International and Warburg Pincus. EQRx abandons its mission of drug price reform and will cut more than half of its employees. Europe faces medicine supply shortages, and Viatris leans into its brand drug portfolio for future growth.